

DEVELOPMENTAL BIOLOGY

Spatiotemporal gating of Stat nuclear influx by *Drosophila* Npas4 in collective cell migrationJhen-Wei Wu¹, Chueh-Wen Wang¹, Ruo-Yu Chen¹, Liang-Yi Hung¹, Yu-Chen Tsai², Yu-Ting Chan¹, Yu-Chiuan Chang^{3*}, Anna C.-C. Jang^{1*}

Collective migration is important to embryonic development and cancer metastasis, but migratory and non-migratory cell fate discrimination by differential activity of signal pathways remains elusive. In *Drosophila* oogenesis, Jak/Stat signaling patterns the epithelial cell fates in early egg chambers but later renders motility to clustered border cells. How Jak/Stat signal spatiotemporally switches static epithelia to motile cells is largely unknown. We report that a nuclear protein, Dysfusion, resides on the inner nuclear membrane and interacts with importin α/β and Nup153 to modulate Jak/Stat signal by attenuating Stat nuclear import. Dysfusion is ubiquitously expressed in oogenesis but specifically down-regulated in border cells when migrating. Increase of nuclear Stat by Dysfusion down-regulation triggers invasive cell behavior and maintains persistent motility. Mammalian homolog of Dysfusion (NPAS4) also negatively regulates the nuclear accumulation of STAT3 and cancer cell migration. Thus, our finding demonstrates that Dysfusion-dependent gating mechanism is conserved and may serve as a therapeutic target for Stat-mediated cancer metastasis.

INTRODUCTION

Tissue morphogenesis during animal development and homeostatic wound healing relies on collective cell migration. Impaired cell migration causes devastating pathologies such as chronic wounds, birth defects, and immune deficiencies (1). Notably, cancer metastasis, whereby tumor cells invade neighboring tissues and migrate to distal organs, is a leading cause of patient death (2). However, it remains unclear how the population size of migratory cells is restricted by signaling pathways and how extracellular signals are ranked and integrated at the nuclear structure by gating the nuclear import of transcriptional factors, which is crucial to not only morphogenesis in animal development but also collective cancer metastasis. An increasing number of studies indicate that nucleocytoplasmic components or nuclear pore complexes (NPCs) are not just structural proteins gating macromolecules transport by size; some NPC subunits or karyopherin family proteins have different stoichiometry at the pore or differential expression during development (3, 4), which acts as a scaffold to recruit transcription factors for neuroprogenitor differentiation or for muscle development (5). Defects in nuclear transport not only impairs development, gametogenesis, or immune deficit due to insufficient nuclear accumulation of Smad, Ci, β -catenin, Sox9, NF- κ B (nuclear factor κ B), etc., but also affects the function and survival of motor neurons because of pathological aggregate of the nuclear RNA binding protein, TDP-43, in the cytoplasm (4, 6, 7). Those lines of evidence suggest that multilevel signaling may be controlled by timely delivery of nuclear protein into the nucleus, yet the molecular mechanism remains elusive.

The Janus kinase (Jak)/signal transducer and activator of transcription (Stat) pathway is a key signal perpetuated via the level of nuclear accumulation of phosphorylated Stat (p-Stat) (8–10). Upon

ligand binding, the Jak/Stat receptor induces Jaks to auto-phosphorylate and trans-phosphorylate at select tyrosine residues of the receptor, which creates Stat docking sites. The Stats can then be phosphorylated by Jak, enabling dimerization with the importin α/β complex for nuclear entry (8, 11). During passage through the NPC, Stat is unloaded from the importin α/β complex upon binding to RanGTP, a small guanosine triphosphatase (GTPase) that regulates nuclear transport via guanosine triphosphate (GTP)/guanosine diphosphate (GDP) cycling (11, 12). Given the diverse functions of Jak/Stat signaling, insufficient or excessive activity can induce severe defects in animal development or tumorigenesis (10, 13–15). How different steps of Jak/Stat signaling are regulated has been investigated previously (16). PIAS (protein inhibitor of activated Stat) and Socs (suppressor of cytokine signaling) are conserved from *Drosophila* to mammals and negatively regulate Stat and Jak to maintain balanced signaling activity (17–23). Apart from phosphorylation of Stat resulting in its nuclear transport, the role of the NPC in regulating differential nuclear accumulation of Stat to level Jak/Stat activity remains elusive. It is unlikely that Stat nuclear entry is controlled by the importin α/β complex alone for differential activation of downstream genes, which is an essential process confining migratory and nonmigratory cells in epithelial, stem, and differentiated daughter cells (10, 16, 24–26). Furthermore, although tyrosine phosphorylation is a conserved mechanism for nuclear accumulation of Stats among vertebrates, nucleocytoplasmic shuttling varies among Stat family members (11). Moreover, although Jak/Stat-dependent cancer progression has been reported for ~70% of hematological and solid tumors (27), attempts to develop drugs that target Stat without severe side effects have been unsuccessful. Thus, uncovering the molecular mechanism by which nucleocytoplasmic Stat shuttling is regulated may be crucial to designing intervention strategies for Jak/Stat-mediated cancer metastasis.

In this study, we used border cells derived from *Drosophila* follicular epithelia of egg chambers as a model to investigate how Stat shuttling is regulated at the nuclear membrane, thereby controlling the size of migratory cell clusters. Border cells migrate as a group, with two polar cells being hauled by six to eight motile cells. Cell

Copyright © 2022
The Authors, some
rights reserved;
exclusive licensee
American Association
for the Advancement
of Science. No claim to
original U.S. Government
Works. Distributed
under a Creative
Commons Attribution
NonCommercial
License 4.0 (CC BY-NC).

¹Department of Biotechnology and Bioindustry Sciences, National Cheng Kung University, 1 University Rd, Tainan City 70101, Taiwan. ²Department of Life Science and Life Science Center, Tunghai University, No.1727, Sec.4, Taiwan Boulevard, Taichung City 407224, Taiwan. ³Institute of Biomedical Sciences, National Sun Yat-sen University, 70 Lien-Hai Rd, Kaohsiung 80424, Taiwan.

*Corresponding author. Email: ycc@mail.nsysu.edu.tw (Y.-C.C.); ccjang@ncku.edu.tw (A.C.-C.J.)

number in the cluster is determined by the Jak/Stat activity triggered by Upd (Unpaired), which is the *Drosophila* homolog of interleukin-6 (IL-6) and is secreted from the polar cells (24). Once Upd binds to its receptor, Domeless, graded Jak/Stat activity patterns the anterior-posterior axis of egg chamber development and instructs follicular epithelia cell fates (28–30). At stage 9 of oogenesis, Jak/Stat activity renders only six to eight follicular cells motile, forming a border cell cluster. Defects in Jak/Stat components hamper recruitment of migratory cohorts, whereas Jak/Stat hyperactivity leads to addition of extra invasive border cells (24). Apart from governing migratory cell fate, Jak/Stat activity is also required for maintaining persistent migration, because temporary blockage of the signaling impedes border cell movement by shifting *stat^{ts}*, a temperature-sensitive allele of *stat*, to nonpermissive temperature for 30 min (25). Global analyses for border cell migration further reveal that *slow border (slbo)*, the downstream target of Jak/Stat, spatially increases mRNA levels of several cytoskeleton-associated proteins by 2- to 18-fold in border cells (31, 32). Collectively, acquisition of motility for border cells demands a higher level of Jak/Stat signaling. Because the induction level of Jak/Stat signaling is the pivotal step in inducing border cell motility, spatiotemporal control of Jak/Stat to dampen Stat activity in non-migratory follicle cells becomes critical (33, 34). In that regard, most previous studies have focused on Jak/Stat phosphorylation, transcriptional control of Stat, or Stat RNA/protein stability (10, 33, 34). However, how nuclear transport of Stat is modulated has not been explored in detail, although it could be vital to how Jak/Stat signaling is balanced during tissue morphogenesis and in cancer cell migration (16).

Here, we demonstrate that a basic helix-loop-helix (bHLH) nuclear protein [Dysfusion (Dysf)] acts as a negative regulator of Stat nuclear import in border cell migration. Overexpression of Dysf impairs border cell recruitment and persistent migration. Consistently, *dysf* loss-of-function mutation ectopically activated Jak/Stat signaling, leading to extra migrating border cells. Dysf is ubiquitously expressed on the nuclear membrane of *Drosophila* follicle cells, but its expression progressively declines in border cells and becomes undetectable as they reach the oocyte. In a biochemical screen, we identified *Drosophila* importin $\alpha 2$, Pendulin (Pen), and the importin β family member karyopherin $\beta 3$ (Kary $\beta 3$) in the pull-down complex. Mechanically, Dysf binds to the importin β binding (IBB) domain of Pen, which blocks its interaction with Kary $\beta 3$ and impairs Stat nuclear import. A forward genetic screen further identified Nup153 genetically interacting with Dysf to regulate border cell migration. Evolutionarily, we show that the mammalian homolog of Dysf, neuronal PAS domain protein 4 (Npas4) (35), plays a similar role in Jak/Stat-mediated cancer cell migration. Our work provides insights into how Dysf spatiotemporally regulates Jak/Stat signaling by acting as a gatekeeper at the inner nuclear membrane to modulate nuclear translocation of Stat, explaining the long-standing mystery of why Jak/Stat signaling displays surge-like behavior during border cell migration. Moreover, our discovery of a novel role for Npas4 in suppressing Jak/Stat signaling-mediated cancer cell migration may represent a new treatment strategy for targeting Stat-mediated metastases.

RESULTS

Identification of Dysf as a suppressor of Jak/Stat signaling

Jak/Stat signaling in early oogenesis is required for stalk cell formation. Germ line-derived Delta signaling induces polar cell formation,

and the Jak/Stat ligand Upd is secreted from polar cells to promote stalk cell fate (fig. S1A) (29, 30). However, border cells are not recruited until stage 9 of oogenesis, although Jak overexpression in early oogenesis cannot induce precocious cluster formation. The only way to induce precocious migration of border cells is coactivating Jak/Stat and ecdysone signaling, the latter of which determines the timing of border cell detachment (36). Thus, we hypothesized that there might be two levels of Jak/Stat signaling, by stage 9, with a lower level harnessing follicle cell differentiation and a higher one recruiting border cells to initiate migration upon ecdysone signaling activation. To test that hypothesis, we assayed fluorescence signal of Stat92E-green fluorescent protein (GFP) to represent Jak/Stat activity during *Drosophila* oogenesis (37). The GFP reporter was expressed in the follicular precursors of germaria, with expression increasing gradually as the egg chambers developed, before ultimately being restricted to the anterior/posterior follicles and border cells (Fig. 1A), which is consistent with previous studies (28, 30, 38). Quantitative analysis revealed a significant increase in Stat92E-GFP expression after stage 8, with maximal levels in the migrating border cells. A similar pattern was observed during stages 9 to 10 in posterior follicle cells, but the expression levels were lower than that of border cells (Fig. 1B). Consequently, we hypothesize a temporal switch requiring a suppressor or activator to regulate Jak/Stat signaling activity in border cells. In a forward genetic screen, Dysf overexpression via the GAL4/UAS system (39, 40) impeded border cell movement, with 99% of border cells in 183 stage 10 egg chambers not migrating (Fig. 1, D and E). Notably, nearly 98% of those cells did not even detach from the anterior epithelium (Fig. 1D), unlike for control egg chambers (Fig. 1, C and E). Dysf overexpression also greatly reduced the number of cells expressing Stat92E-GFP in the anterior terminals of egg chambers (Fig. 1, F, F', H, and H'). After carefully scrutinizing border cells marked with *slbo-GAL4*-driven UAS-*mCD8-gfp* and Eyes absent (Eya) staining (41), we found that only 22.58% of egg chambers contained a shrunk cluster with a decrease in border cell number from 5.6 to 3.9, and the rest (77.42%) failed to form a cluster (Fig. 1, G to K). To explore how Dysf affects Jak/Stat signaling, we randomly induced UAS-*dysf* by *actin-GAL4* in individual border cells by means of a Flip-Out technique (42) to analyze its effect on Stat92E-GFP signal. Overexpressing Dysf in single border cells resulted in a 30% reduction in Stat92E-GFP signal (fig. S1, B to H) and delayed group cell migration (fig. S1I). We further assessed the effect of *dysf* on individual cell motility by quantifying clone position in the migrating cluster. Similar to the previous report, the control clones expressing UAS-*lacZ* randomly rotated within the cluster during migration (fig. S1J) (43). However, 88.2% of *dysf*-expressing cells were found to stay in the trailing part (fig. S1, B to D and J), and some of them even lagged behind the main cluster (fig. S1, E to G). These results indicate that up-regulation of *dysf* suppresses Jak/Stat-dependent motility and specification in border cells.

To trigger signal activation, Stat proteins must first be phosphorylated by Jak to undergo dimerization and then translocate into the nucleus to bind the consensus DNA binding site (44, 45). Therefore, we examined the phosphorylation status of Stat in border cells by means of anti-p-Stat staining (Fig. 1, L to N). Consistent with the expression pattern of Stat92E-GFP, p-Stat staining is increased in border cell nuclei during migration (Fig. 1, L and M, white arrowheads, and fig. S2, A to C). The fluorescence intensity of p-Stat staining remains stable until stage 7 and then gradually increases and reaches the peak at early stage 9 (from 2.6- to 39-fold; fig. S2E,




Fig. 1. Dysf represses Jak/Stat signaling during *Drosophila* oogenesis. Confocal micrographs of *Drosophila* egg chambers showing border cells (bc; arrowheads) migrating through nurse cells (nc). Anti-DE-cadherin staining [red in (A), (C), and (D)] labels cell margins, and DAPI (4',6-diamidino-2-phenylindole; blue) marks nuclei. All UAS transgenes were driven by *slbo-GAL4*. (A) The *Stat92E-GFP* reporter (green) reveals Stat activity during *Drosophila* oogenesis from the germarium (yellow arrow) to egg chambers (red arrow). (B) Fluorescence intensity of Stat92E-GFP in *Drosophila* oogenesis. (C and D) Dysf overexpression impairs border cell migration. Fasciclin 3 (Fas3; magenta) staining labels polar cells. (E) Quantification of migration defect caused by *dysf* overexpression. The migration path is divided into five sections to quantify the extent of border cell migration. (F and H) Dysf overexpression reduced border cell number in the cluster. *Stat92E-GFP* signal marks border cells (white arrowheads), and phalloidin staining (red) labels cell margins. (G, I, and J) *slbo-GAL4>UAS-mCD8Gfp* marks the cluster morphology, and anti-Eya labels anterior follicle cells. (K) Quantification of Dysf effect on border cells. (L and M) Anti-p-Stat staining (red) displays nuclear accumulation in border cells. Wt, wild type. (N) Dysf overexpression reduced p-Stat accumulation in border cell nuclei. *n* represents the number of egg chambers examined; ****P* < 0.001, two-tailed *t* test. Error bars indicate SD. Scale bars, 20 μ m.

red plot). The nucleus/cytoplasm (N/C) ratio of the p-Stat signal starts to rise at stage 5 and keeps at a similar level (1.65-fold) from stages 6B to 10 (fig. S2E, blue plot). However, overexpressing *Dysf* in border cells reduced the nuclear staining of p-Stat (Fig. 1N and fig. S2D) with a decline in the fluorescence intensity (fig. S2F) and the N/C ratio (fig. S2G). To gain insights into the link between nuclear accumulation of p-Stat and cell motility, we analyzed the N/C ratio of p-Stat in Jak/Stat hyperactivation that can induce extra border cells (24). We ectopically expressed *hopscotch* (*hop*; the *Drosophila* homolog of Jak) and found that the N/C ratio of p-Stat was 1.44 in extra border cells, 1.56 in normal border cells, the front cluster that can reach oocyte, and 1.49 in wild-type border cells (fig. S2H, I and L). This result demonstrates the small fluctuation of p-Stat N/C ratio in Jak/Stat signaling-dependent migration.

Dysf is a transcription factor that dimerizes with Tango (Tgo; a bHLH nuclear protein) to control gene expression for tracheal fusion in *Drosophila* embryogenesis, and it acts downstream of Notch signaling to regulate leg development (46–48). Accordingly, we wanted to ascertain whether *Dysf* functions as a repressor of Jak/Stat signaling by suppressing *stat* transcription. We determined expression of the enhancer trap line *stat*⁰⁶³⁴⁶ (*stat-lacZ*; fig. S3, A to D), acting as a transcriptional reporter of a subset of *stat* expression during oogenesis and eye development (24, 49). There was no significant difference in *stat-lacZ* signal between wild-type and *Dysf*-overexpressing border cells (fig. S3E), indicating that *Dysf* does not transcriptionally control *stat* expression. To further probe epistasis between *Dysf* and *Stat*, we assessed whether *Dysf* overexpression suppresses the multi-cluster phenotype caused by Jak/Stat hyperactivity. As documented previously (24), up-regulation of *upd* or *hop* resulted in two to four border cell clusters within egg chambers, counted with the morphology of migratory cells stained with DAPI (4',6-diamidino-2-phenylindole) and anti-DE-cadherin (Fig. 2, A, B, F, and G). Coexpression of *upd* or *hop* with *dysf* restored the cluster number to one and impeded border cell movement (Fig. 2, C to E and G). Notably, the impact of *dysf* almost outweighed the function of *hop* in terms of cluster formation and cell migration, suggesting that *Dysf* works downstream or in parallel with Jak. Thus, we conclude that *Dysf* suppresses extra border cell specification before high STAT signaling.

To further elucidate the role of *Dysf* in restricting Jak/Stat signaling, we tested whether *dysf* loss-of-function mutation resulted in ectopic Stat92E-GFP expression or additional border cells. Because of lethality, the regular treatment for clone induction led to no *dysf*²-homozygous mutant cells reaching the stage 9 of oogenesis to form border cells. We found that 75% of early-stage egg chambers carrying *dysf*² mutant clones displayed ectopic Stat92E-GFP expression (Fig. 3, D to F, yellow arrows, and fig. S4A), which was not observed in the control *FRT82B* line (Fig. 3, A to C, yellow arrows, and G). However, this phenotype showed incomplete penetrance, meaning that not all *dysf*² mutant clones were able to express ectopic Stat92E-GFP (Fig. 3G and fig. S4B, white arrowheads). In addition, some *dysf*² clones showed follicle epithelial defects in earlier stages, including condensed DAPI staining (fig. S4C) and gaps between twin spots (fig. S4D), but the germline mutation did not delay border cell movement or cause any apparent defect (fig. S4E). Homozygous cells of *dysf*^{1W}, a null allele generated in-house (fig. S5A), also encountered lethality issue. Therefore, we analyzed egg chambers dissected from *dysf*^{2/3} trans-heterozygotes and found that 26% of them had additional migrating clusters (Fig. 3, I and J), which was not the case for

wild-type, *dysf*^{2/+}, or *dysf*^{3/+} lines (Fig. 3, H and J) and resembled the phenotypes resulting from Jak/Stat hyperactivation. Similarly, RNA interference (RNAi)-mediated knockdown of *dysf* also phenocopied the excess in border cell clusters (Fig. 3K), with penetrance increasing from 4 to 16% in response to a longer expression time of *dysf*^{RNAi} (Fig. 3L). The N/C ratio of p-Stat staining of ectopic border cells induced by *dysf* knockdown (1.48) was close to that in the wild-type control (1.51; fig. S2, J, K, and M). To distinguish whether the extra border cells were autonomously induced by *dysf* down-regulation or recruited by excessive polar cells, 1- to 2-day clones were generated to avoid lethality and ectopic polar cell formation. Under this condition, we retrieved very few egg chambers containing multiple *dysf*^{1W} clones that invaded and migrated through the nurse cell cluster (Fig. 3, M to P). Together, we conclude that *Dysf* is a negative regulator constraining Jak/Stat signaling to control border cell recruitment, with loss of *Dysf* elevating Jak/Stat activity and inducing extra migrating cells.

Dysf is located on the inner nuclear membrane where it gates nuclear entry of Stat

Dysf has been identified as a bHLH nuclear protein that is expressed in fusion cells to regulate *Drosophila* trachea development (50). Unexpectedly, rather than the nucleus-wide staining pattern reported previously for *Dysf* (50), we observed that *Dysf* expression was restricted to the nuclear membrane throughout oogenesis, including for germline and follicle cells (Fig. 4, A to F). Specificity of the anti-*Dysf* staining was confirmed with mutant clone analysis (fig. S5, B to D). As border cells began to migrate, staining signal of *Dysf* at the nuclear membrane gradually diminished (Fig. 4, D and E), becoming undetectable at stage 10 when the cluster came into contact with the oocyte (Fig. 4F). To depict the spatial relationship between *Dysf* and the nuclear membrane, we compared patterns of anti-*Dysf* staining with expression signal of GFP-tagged Lamin, a fibrous protein that lines the inner nuclear membrane (Fig. 4, G to G"). Confocal microscopy and Zen software analyses revealed a high colocalization coefficient (0.901) between these two proteins (Fig. 4H). Unlike border cells, the nuclear membrane staining of *Dysf* remains clear in the anterior follicle cells nearby border cells and the posterior follicles (fig. S6, A to C). We quantified the fold change in fluorescence intensity and found that anti-*Dysf* staining in border cells was significantly reduced from 2.58 to 1.19 during stages 8 to 10 (fig. S6D). A gradual decrease from 2.68 to 1.82 in *Dysf* staining was also observed in posterior follicle cells (fig. S6D). To further analyze the anti-*Dysf* distribution, we measured and plotted the fluorescence intensity across the nucleus of border cells and posterior follicles (fig. S6E). In both cell types, the fluorescence intensity profile of *Dysf* staining displays twin peaks at stage 8, indicating enriched signals on the nuclear membrane (arrows, fig. S6, F and G); however, in later stages, border cell profile turns wavy, similar to that of DAPI without specific accumulation (fig. S6F). In contrast, the posterior follicle cells kept the two-peak pattern all the way to stage 10 (arrows, fig. S6G). This observation concludes a spatiotemporal down-regulation of *Dysf* on the nuclear membrane of border cells when border cells start to move at stage 9. To further clarify whether *Dysf* resides on the inner nuclear membrane or in the perinuclear space, we conducted a Duolink proximity ligation assay (PLA), enabling us to examine intramolecular distances to within 40 nm (Fig. 4I) (51, 52). Confocal fluorescence microscopy revealed accumulated PLA foci upon co-incubation of anti-*Dysf* and anti-Lamin antibody (Fig. 4, J and K)




Fig. 2. Dysf suppresses the hyperactive Jak/Stat phenotype in border cells. (A to F) Confocal micrographs showing border cell clusters (red arrowheads) in stage 10 egg chambers of the indicated genotypes. Anti-DE-cadherin staining (green) and DAPI (blue) mark cell margins and nuclei, respectively. Overexpression of *upd* or *hop* induces extra border cell clusters (A and B, yellow arrowheads). Egg chambers coexpressing *dysf* with *upd* or *hop* have one border cell cluster displaying migration delay (D and E), similar to the phenotype arising from *dysf* expression (C). Double UAS-*lacZ* serves as the control (F). (G) Quantitative assessment of the number of migrating clusters with indicated genotypes. *n* represents the total number of egg chambers examined; ****P* < 0.001, two-tailed *t* test. The box plot shows the medians (black lines), means (red lines), the 25th and 75th range (boxes), and the 5th and 95th percentiles (whiskers). Scale bars, 20 μ m.

but not in negative controls containing preimmune serum or single primary antibody alone (Fig. 4, J and L to N). Moreover, anti-Dysf antibodies paired with antibodies against major components of the NPC, such as mAb414 that detects FG repeat-containing nucleoporins and Nup107, interacted in PLA (fig. S7, A to C). In contrast, no proximity was detected by PLA for Dysf and outer nuclear membrane proteins, including MSP-300 and Klarsicht (fig. S7, A, D and E) (53, 54). Quantitative analyses also demonstrate significant interactions of Dysf with Nup107 and central FG repeat-containing nucleoporins in the follicular epithelium (fig. S7, F to H). These PLA results demonstrate that Dysf is located on the inner nuclear membrane and, more precisely, near the nuclear lamina and NPC.

Given its subcellular localization, we wondered whether Dysf localizes close to the nuclear lamina and NPC to regulate nucleocytoplasmic transport of Stat. To address that possibility, we examined the expression pattern of *stat92e-stat::gfp* that encodes a Stat protein fused with GFP under control of its endogenous promoter (55). Dissimilar to anti-p-Stat staining, visualization of Stat::GFP distribution does not require a complicated fixation process or phosphatase inhibitor treatment. In addition, previous investigation revealed p-Stat staining as a useful tool for high-threshold Jak/Stat activity in stages 9 to 10 of oogenesis, but for signaling activity below the threshold, p-Stat antibody is not sensitive enough to detect the signal fluctuation (56). Thus, we applied *stat92e-stat::gfp* to detect the




Fig. 3. Down-regulation of *dysf* results in recruitment of extra border cells. (A to C) Immunofluorescence micrographs showing *Stat92E-GFP* (green) expression patterns in egg chambers. White arrowheads indicate egg chamber terminals. (D to F) The *dysf²* mutant clone [red fluorescence protein (RFP)–negative; dotted circle] presents ectopic *Stat92E-GFP* signal (yellow arrows) relative to control clones [yellow arrows in (A) to (C)]. (G) Quantification of ectopic *Stat92E-GFP* in indicated genotypes. (H and I) *dysf^{2/3}* displays multiple border cell clusters (yellow arrowheads). (J) Quantification of extra border cells in *dysf^{2/3}*. (K) Knocking down *dysf* induced extra border cell clusters (yellow arrowheads). Anti-FasIII labels polar cells. (L) Quantification of ectopic cluster formation by *dysf* RNAi knockdown. Colors indicate the border cell cluster number. (M to P) Three-dimensional projection exhibits freely migrating border cells (white arrow) under *dysf^{Ww}* mutation (RFP-negative; white outline). All white arrows indicate border cells reaching the oocyte border. Enlargements of the boxed region are shown in (N) to (P). Anti-Eya stains follicle cells and border cells [red in (H) and (I); green in (M) and (P)]. DE-cadherin staining (green) labels cell margins (H, I, and K). DAPI (blue) marks all nuclei. Scale bars, 20 μ m.




Fig. 4. The nuclear membrane of border cells displays a gradual decline in Dysf expression. (A to G) Immunofluorescence micrographs showing anti-Dysf staining during *Drosophila* oogenesis [red in (A) to (C), (G), and (G''); white in (D) to (F)]. Arrowheads indicate nuclear membrane staining of Dysf in border cells (white) and nurse cells (yellow) in early stage 9 (D), mid-stage 9 (E), and stage 10 (F) egg chambers. The dotted white line denotes the oocyte border. (G to G'') Colocalization of anti-Dysf staining (red) and Lamin-GFP (green) signals on nuclear membrane in main-body follicles (arrowheads). (H) Colocalization coefficient for Dysf and Lamin-GFP. n indicates the number of nuclei examined. (I) Schematic illustrating detection of the Dysf-Lamin interaction by proximity ligation assay (PLA). (J) Quantifications of PLA signals using the indicated antibodies. The line boundaries show the SD of signal distributions, with the midline marking the average. (K to N) Confocal micrographs of egg chambers showing PLA reactions (red) with indicated antibodies. DAPI (blue) labels nuclei. n represents total sample size; *** $P < 0.001$, two-tailed t test. Error bars indicate SD. Scale bars, 25 μm (A to F) and 20 μm (G and K to N).

nuclear translocation of Stat. In the early stages of oogenesis, the intensity of Stat::GFP was relatively low and gradually increased from 6.7- to 14.3-fold during stage 8 to mid-stage 9 (fig. S8, A to E). Higher Stat::GFP signal was observed in border cell nuclei during migration (Fig. 5, A and B, yellow arrowheads), and the N/C ratio of fluorescence signal increased from 1.9 to 2.2, while border cells start to move at stage 9 (fig. S8F, red plot). By contrast, the N/C ratio of nonmigratory follicle cells remained lower than the anterior ones or border cells, staying at 1.53 to 1.61 during stage 6b to mid-stage 9 but rising to 1.77 at stage 10 (fig. S8F, blue plot). Overexpression of *Dysf* affected the cytoplasmic and nuclear distribution of Stat::GFP (Fig. 5, A to C), with the N/C ratio dropping to 1.19 (fig. S9E). To further examine the effect of *Dysf* on the cellular distribution of Stat::GFP and to test its conservation across cell types, we scrutinized Stat::GFP in the salivary glands of *Drosophila* larvae because of the larger cell size that can improve nucleocytoplasmic visualization (Fig. 5, D to G). In wild-type salivary glands, Stat::GFP was found predominantly in nuclei (Fig. 5, D to D''). However, under the condition of *Dysf* overexpression, Stat::GFP also accumulated at the periphery of the nuclear membrane (Fig. 5, E to E'') and outside the lamin meshwork (Fig. 5, G and G'). To quantify this effect, we measured the N/C ratio of Stat::GFP signal in the salivary gland cells and observed a reduction from 2.40 to 0.57 upon *Dysf* overexpression (Fig. 5J). Similarly, the ratio of p-Stat staining also decreased from 2.41 to 0.92 by *Dysf* up-regulation (Fig. 5, H, I, and K). We next examined the Stat::GFP signal in extra recruited border cells induced by overexpression of *hop* or *dysf* RNAi, and found that N/C ratios of Stat::GFP in these migrating cells were between 1.95 and 1.76, respectively, close to 1.83 in wild-type stage 10 border cells (fig. S9, A to E), but higher than 1.6 and 1.54 in nonmigratory cells at stage 9 to mid-stage 9 (fig. S8, A'' to D'' and F, blue plot). Observations here demonstrate that up-regulation of *Dysf* reduced the amount of nuclear Stat, but conversely, down-regulation of it led to an increase in Stat N/C and induced extra border cells, suggesting a role for *Dysf* in modulating Stat nuclear import to control border cell migration.

To uncover the molecular mechanism by which *Dysf* regulates Stat activity in situ and in vivo, it is critical to purify *Dysf*-associated proteins under native conditions. Thus, we generated the *N-APEX2-dysf* knock-in fly line that harbors an engineered ascorbate peroxidase (*APEX2*) inserted into the *dysf* locus to form a fused gene under endogenous promoter control (fig. S5A). *APEX2* is one of the most efficient enzymes for proximity labeling, with proteins of interest fused with *APEX2* tagging nearby proteins with biotin, enabling subcellular protein compartments to be mapped or the interacting partners of target proteins to be purified by means of streptavidin beads (52, 57, 58). We compared protein expression in fly ovaries treated with or without biotin labeling by blotting with streptavidin^{HRP}. Seven slices were excised from the protein gel in alignment with the blot and then analyzed by liquid chromatography with tandem mass spectrometry (LC-MS/MS; Fig. 6A). By doing so, we identified 34 candidate genes, including histone binding proteins, nuclear transporters, a GTPase, ribosomal proteins, and RNA binding proteins, among others. Notable among them were *Drosophila* importin α 2, Pen, and Kary β 3 (of the importin β family), indicating that they might participate in *Dysf*-mediated nucleocytoplasmic Stat translocation. We prioritized analysis of the interaction between Pen and *Dysf*. Given that *APEX2*-mediated biotin labeling requires proximity between two proteins, we used a pull-down assay to determine

whether Pen and *Dysf* interact. Consistent with our blotting result (Fig. 6A), we found that hemagglutinin-tagged *Dysf* (*Dysf*::HA) bound to bacterially expressed Pen fused with a 6xHis::MBP tag (His, histidine; MBP, maltose binding protein) (Fig. 6B). Stat binds the armadillo repeats of importin α and forms a complex with importin β for nuclear transport (11). Given that *Dysf* also binds Pen and negatively regulates the nuclear localization of Stat, we postulated that the association between *Dysf* and Pen might interfere with the formation of the trimeric complex comprising importin α/β and Stat. Accordingly, we constructed various truncation mutants of Pen protein to determine which domain of Pen is responsible for interacting with *Dysf*. Glutathione *S*-transferase (GST) pull-down assays revealed that the IBB domain (covering amino acids 1 to 63) of Pen showed the strongest binding affinity for *Dysf* (Fig. 6C), relative to its armadillo repeats and the SAR domain (Fig. 6C). Our domain analysis indicates that rather than disrupting the Stat-Pen association, *Dysf* may modulate Stat translocation across the nuclear membrane by binding to Pen to interfere with Pen/Kary β 3 complex formation. To test this hypothesis, we carried out a competition assay to appraise the binding affinity of Pen for *Dysf* and Kary β 3. A pull-down assay showed that *Dysf*-Pen binding was not affected in the presence of abundant MBP::Kary β 3 recombinant protein (Fig. 6D, top panel). Moreover, we found that MBP::Kary β 3 interacts with Pen::GST (Fig. 6D, bottom panel). Next, we tested whether the *Dysf*-Pen interaction leads to dissociation of the Stat-Pen complex. We observed that Stat bound to Pen and formed a stable complex with *Dysf*, demonstrating that *Dysf* does not hamper the Stat-Pen association to attenuate Stat nuclear entry (Fig. 6E). These results suggest that the higher affinity of *Dysf* for the IBB domain of Pen may influence importin β -dependent nucleocytoplasmic transport. In a prevailing model without cargoes, importin α undergoes internal binding between its IBB domain and armadillo repeats (59). However, upon importin α binding to cargo, its IBB domain is exposed to importin β , which carries the transport complex through the NPC by interacting with the FG domain of Nups (60–63). Combining this conventional model with our findings, *Dysf* may occupy the IBB domain of Pen to restrict interaction between Kary β 3 and the Pen-Stat complex, thereby impairing delivery of Stat into the nucleus. If our model is correct, elevating Pen expression should counteract the effect of *dysf* up-regulation to increase the flow of Stat into the nucleus. In comparison to the control of UAS-*dysf* with 25.3% of border cells reaching the oocyte border, 36.3% of clusters that coexpressed Pen and *Dysf* completed the migration path, indicating a partial rescue of *Dysf*-induced migration defect by UAS-*pen* (Fig. 6F). Moreover, Pen overexpression also suppressed the phenotype of nuclear down-regulation of p-Stat caused by *Dysf* (Fig. 6, G and H, and fig. S2N). To reveal how Nup proteins participate in *Dysf*-mediated Stat transport, we performed a modified screening for any NPC component that could be linked to the *Dysf*-induced migration defect when overexpressed or down-regulated. After systematically examining 28 Nup genes, we noted that down-regulation of *nup153* by RNAi knockdown or incorporation of a transposon-inserted mutant allele not only significantly suppressed the migration delay caused by *Dysf* (fig. S10, A and B) but also restored nuclear accumulation of p-Stat (fig. S10, C and D). Together, based on our findings, we hypothesize that *Dysf* resides on the nuclear lamina to attenuate passage of Stat through the NPC by binding to the IBB domain of Pen, thereby promoting dissociation of Kary β 3 from the Pen-Stat complex, which results in cargo being retained at the inner




Fig. 5. Suppression of Stat nuclear import upon Dysf overexpression. (A to C) Confocal images of GFP-tagged Stat distribution (green) in stage 9 or 10 egg chambers stained with DAPI (blue) to mark nuclei. Border cells indicated by arrowheads are shown below at higher magnification (A' to C'). Stat::GFP expression (green) (D to G) and anti-p-Stat staining (H and I) in the salivary glands of the indicated genotypes, as revealed by immunofluorescence staining, and boxed regions are enlarged and displayed below. DAPI labels nuclei (white), and anti-Lamin (red) staining defines the boundary between the nucleus and cytoplasm. Quantitative assessment of the impact of Dysf on Stat nuclear localization by examining the nucleus:cytoplasm ratio of Stat::GFP (J) or anti-p-Stat (K) fluorescence signal. *n* indicates the number of salivary glands examined; ****P* < 0.001, two-tailed *t* test. Error bars indicate SD. Scale bars, 20 μ m.




Fig. 6. Dysf-Pen interaction regulates Stat nuclear import. (A) Biotinylated proteins were pulled down by streptavidin beads and detected by streptavidin^{HRP}. SDS-polyacrylamide gel electrophoresis (PAGE) gels subjected to LC-MS/MS analysis were stained with Coomassie blue. (B) Pull-down assay validated the interaction between Dysf and Pen. (C) Schematic showing full-length and truncated Pen proteins with known domains. GST pull-down assay (bottom) demonstrated interaction of Dysf with Pen variant proteins. (D and E) GST pull-down assay revealed the impacts of Kary β 3 (D) or Stat (E) on Dysf-Pen association. (F) Quantification of border cell migration defects in indicated genotypes. Coexpression of *pen* partially rescues *dysf*-induced migration defect. (G and H) Fluorescence micrographs of stage 10 egg chambers stained with anti-p-Stat (green) and DAPI (blue). Arrowheads indicate an even distribution of p-Stat under the condition of Dysf overexpression (G to G’). Arrows highlight nuclear accumulation of p-Stat in cells coexpressing *dysf* and *pen* (H to H’). *n* is the total number of egg chambers examined; **P* < 0.05, two-tailed *t* test. Error bars indicate SD. Scale bars, 20 μ m.




Fig. 7. The human homolog of Dysf, Npas4, impairs Stat3 nuclear localization and cancer cell migration. Confocal images of cancer cells stained with anti-Stat3 antibodies (red) and DAPI (white). After IL-6 stimulation, control cells transfected with GFP (green) revealed an accumulation of Stat3 in nuclei [yellow arrows in (A) to (C) and (G) to (I)]. Transfection of GFP::Npas4 (green) led to a lack of Stat3 signal in nuclei [white arrowheads in (D) to (F) and (J) to (L)]. (M) Crystal violet–stained (purple) Hep3B cells that crossed the transwell chamber membrane. (N) Quantification of our transwell migration assay (** $P < 0.01$, two-tailed t test; error bars indicate SEM). (O) Coimmunoprecipitation analysis demonstrated Npas4-Kpna2 interaction. (P) GST pull-down assay confirmed Npas4-Kpna2 interaction. (Q) Model of how Dysf gates nuclear import of Stat. Dysf protein resides on the inner nuclear membrane and binds to Pen via its IBB domain. Left: By stage 9, Dysf-Pen interaction reduces nuclear translocation of Stat. Right: In border cells, the gradual decrease of Dysf releases the constraint on Stat nuclear influx, inducing higher signaling activity and leading to cluster formation that maintains persistent migration. Nup153 serves as an additional gatekeeper modulating nuclear shuttling of Stat in border cells. Scale bars, 10 μm (A to L) and 500 μm (M).

nuclear membrane (Fig. 7Q). The spatial decline in Dysf protein within stage 9 border cells increases Stat inflow into the nuclei, escalating Jak/Stat signaling to induce formation of a cell cluster and prompting persistent cell migration.

Our previous study demonstrates that ecdysone serves as a temporal signal to conduct border cell detachment and coactivation of ecdysone and Jak/Stat signaling induces border cell migration 12 hours in advance (36). Therefore, we wanted to test whether this precocious movement can be achieved by ecdysone hyperactivation with *dysf* down-regulation instead. In many cases, coexpression of UAS-*dysf*^{RNAi} and UAS-*tai*(ΔB), the constitutive-active form of the ecdysone receptor coactivator *taiman*, led to egg chamber degeneration, but we still observed five early-detached border cell clusters in total 48 stage 8 egg chambers examined (fig. S11, A, B, E, and F). However, this early migration phenotype was not found in overexpression of UAS-*tai*(ΔB) or UAS-*dysf*^{RNAi} alone (fig. S11, C to F). These data showed that *dysf* hypoactivity can replace Jak/Stat hyperactivity to trigger precocious border cell movement under excessive ecdysone trigger, namely, *dysf* functions as a temporal regulator that controls Jak/Stat-dependent migration in border cells.

Suppression of Stat3 nuclear import and cancer cell migration by mammalian Npas4

Dysregulation of Stat proteins has been reported previously for cancer cell lines and patient-derived tumor tissues, with most cancer treatment strategies targeting Jak/Stat signaling designed to inhibit phosphorylation of Jak or Stat (64–66). Inhibitors to suppress general nuclear translocation are undergoing clinical trials for the treatment of hematological or solid tumors, but to date, they have displayed significant toxicity in patients (67). Therefore, selective approaches that block Stat nuclear transport have been proposed to reduce side effects (11). However, an interaction molecule that can prevent Stat nuclear localization in cancer cells has yet to be developed. Moreover, several genes homologous to those involved in *Drosophila* border cell migration have been implicated in regulating cancer progression (1, 16, 68, 69). In search of the correlation between Stat and the human homolog of Dysf (35), Npas4, in cancer development, The Cancer Genome Atlas (TCGA) data mining was performed and revealed an inverse gene profile of these two genes (70, 71). Npas4 belongs to the bHLH-Per-Arnt-Sim (PAS) family and participates in memory formation (72). The Pas1 domain of Dysf shares 54% identity with the Pas domain of Npas4, and overall sequence identity in amino acid is 25%. In Stat-hyperactivated cancer cells, Npas4 expression is very low or barely detected (70). Accordingly, we extended our study to explore whether Npas4 operates via a similar mechanism to suppress Jak/Stat signaling. To investigate the effect of Npas4 on nuclear Stat3 translocation and invasive behavior, we transfected it into the cancer cell lines Hep3B and HCT116, both of which show high level of Stat3 expression. Following IL stimulation, we observed that anti-Stat3 signal was enriched in the nuclei of both sets of control cancer cell lines (Fig. 7, A to C and G to I), but Stat3 signals were reduced in GFP::Npas4-transfected cancer cell lines (Fig. 7, D to F and J to L). The nuclear staining of p-Stat3 was also reduced by Npas4 overexpression (fig. S12). Npas4 significantly impaired IL-6/Stat3-mediated migration in a transwell assay (Fig. 7, M and N). Moreover, GFP::Npas4 can be coimmunoprecipitated with the human homolog of Pen, karyopherin α 2 (Kpna2) (Fig. 7O), and the direct interaction was further confirmed by GST pull-down assay (Fig. 7P). These results provide functional evidence supporting the

idea that the human homolog of Dysf, Npas4, can also antagonize Jak/Stat signaling in cancer metastases.

DISCUSSION

In response to a variety of signals such as morphogens, cytokines, hormones, or stress signals derived from pathogens, tissues must integrate all these inputs and react differentially by modulating expression of various genes. To do so, an array of positive and negative regulators must be orchestrated to define expression boundaries, which is the key to segregating stem cells and differentiated daughter cells in the niche, tissue patterning during embryogenesis, as well as the static and migratory cells of tissue morphogenesis and cancer metastases. Jak/Stat signaling is an example of precise control of gene activation, although its ligand emanates from a very localized source without significant differences in concentration. The Jak/Stat ligand Upd is secreted from anterior polar cells to frame the anterior epithelial pattern of egg chambers during *Drosophila* oogenesis, but only six to eight cells adopt a mesenchymal cell fate because of higher Jak/Stat signaling (24). Thus, suppression of excessive Stat activity in nonmigratory cells is a critical mechanism by which additional recruitment of extra follicle cells is prevented, as also observed for tissue morphogenesis and cancer cell invasion (73). A previous study showed that *apontic* (*apt*), a downstream gene of Stat, suppresses Jak/Stat signaling via auto-feedback to limit border cell number (33). *apt* down-regulates *stat* via its downstream target, miR-279, which targets the 3' untranslated region (3'UTR) of *stat* to suppress gene expression (34). The negative feedback regulation established by *apt/miR-279* accounts for how Stat activity is attenuated in a broad domain of anterior follicle cells to constrain the transmitted effect of Upd secreted from polar cells. However, in the initial stage, anti-Apt and anti-Stat staining signal overlaps in border cell precursors (33), indicating that the feedback loop cannot suppress Stat expression or fully account for border cell fate determination. Our study unveils an additional mechanism by which Stat activity can be differentially controlled by the degree of Stat nuclear import to determine cell fate, motile border cells, or static follicles (Fig. 7Q). Our APEX2-based screen uncovered a physical association between Dysf and Pen, and biochemical and genetic analyses show that Dysf gates nuclear import of Stat. Upon interacting with Dysf, the IBB domain of Pen dissociates from importin β , thereby impairing Stat transport across the nuclear membrane. In the NPC, the FG-rich repeat Nup proteins form a hydrogel-like molecular sieve that prevents diffusion of nonspecific cargoes (74). During nuclear import, the transport complexes carry cargoes across the nuclear membrane by interacting with Nup proteins via importin β , rendering importin α/β part of the molecular sieve modulating nucleocytoplasmic transport (75). In our screen, we also identified the NPC component, Nup153, as part of the regulatory system. Suppression of nuclear Stat translocation by Dysf is dosage dependent because cell motility and nuclear Stat import are both rescued in a genetic background of *pen* overexpression or *nup153* down-regulation. This scenario is consistent with a previous observation that Ran-GTP, importin β , and Nup153 form a higher-order complex to modulate permeability in the nuclear basket (76). Moreover, when Nup153 dosage is reduced, more cargoes such as Stat proteins tend to be translocated into the nucleus. Before stage 9 of oogenesis, endogenous Dysf and Nup153 partially retain the importin α /Stat complex at the nuclear face of Nup to prevent Stat from binding its downstream genes (Fig. 7Q). We found

that 26% of egg chambers carrying a *dysf* mutation had extra migratory clusters, suggesting that Dysf fine-tunes the threshold of Stat activity. Persistent expression of Dysf in nonmigratory follicle cells ensures cell fate stability by preventing perturbations of Jak/Stat activity surpassing the threshold to ectopically induce cell motility. However, once Jak/Stat suppression is lost, extra border cells are induced. Progressive degradation of Dysf at the nuclear membrane of border cells unleashes importin α /Stat complexes associated with Dysf proteins up to stage 9. This temporal regulation, the decline of Dysf at stage 9, is a critical step for border cell fate specification. In combination with ecdysone hyperactivation, precocious down-regulation of *dysf* resulted in early detachment and formation of migrating clusters. This finding demonstrates that Dysf takes part in the spatiotemporal circuit integrated with Jak/Stat and ecdysone signaling to schedule border cell migration. In addition, a previous study has shown that the IBB domain of importin α displays auto-inhibitory activity by binding to its own NLS (Nuclear Localization Signals)-cargo binding pocket, resulting in cargo dissociation in the nucleus (77). Thus, newly unleashed Pen/Stat complexes may disassemble via this auto-inhibitory mechanism. Alternatively, the released Pen/Stat complexes may rebind to importin β , follow the conventional pathway to transit the NPC, and then disassemble by interacting with Ran-GTP (61).

Furthermore, quantitative analyses reveal that slight alternation of the N/C ratio of p-Stat staining or Stat::GFP can significantly affect border cell migration in *hop* hyperactivation or *dysf* dysregulation by RNAi knockdown or overexpression. This result is also consistent with that of the previous investigation, in which a 30-min shift to nonpermissive temperature hindered border cell motility under *stat^{fs}* background (25). Despite a 114% rise in Stat::GFP expression from stage 8 to mid-stage 9 (fig. S8E), the gradual decline of Dysf from stage 8 to early stage 9 followed by sequential increase of Stat::GFP nuclear import, a 16% increase in the N/C ratio (fig. S8F), boosts Jak/Stat signaling activity to the highest level at mid-stage 9 of oogenesis (Fig. 1B). However, we also observed a significant down-regulation of *Stat92E-GFP* in stage 10 border cells when the N/C ratio of Stat::GFP declined and the Dysf staining was almost undetectable. This observation implies an additional mechanism beyond Dysf to attenuate Stat activity, by which Stat may undergo nuclear export and degradation after mid-stage 9. Identification of the novel attenuation mechanism would further fully elucidate the differential control of Stat. In addition, GFP::Npas4 transfection reduced anti-p-Stat or anti-Stat staining not only in the nucleus but also in the cytoplasm in cancer cells. It is likely that the cytoplasmic p-Stat proteins may be dephosphorylated by phosphatases or subjected to proteasome degradation as reported in previous studies (9, 78). However, we cannot exclude the possibility that Npas4 may suppress Stat expression apart from its function on nucleocytoplasmic transport. All of these questions left unaddressed are of great interest to investigate in the future.

Jak/Stat signaling is a key process in several cellular functions, including cell proliferation, angiogenesis, differentiation, survival, and apoptosis, with Jak/Stat dysregulation contributing to diverse pathological defects such as solid tumors and cancer metastases (27). Aberrant activation of Stat3 is estimated to occur in more than 70% of cancers (73, 79). Our findings demonstrate that the human homolog of Dysf, Npas4, plays a similar role in negatively regulating Stat-dependent cancer cell migration. Inhibitors or monoclonal antibodies targeting the IL-6/Jak/Stat3 axis are currently under development and hold promise as antitumor proliferation therapeutics (80). The major limitation of these therapies is the immunosuppression

resulting from general inhibition of Jak/Stat-dependent immune responses, which can offset the antitumor effects of these treatments (81). Thus, tissue-specific biomarkers beyond the Jak/Stat core components are needed for more targeted treatments, with Npas4 revealed by our work potentially representing a novel target for therapeutic development.

MATERIALS AND METHODS

Drosophila strains and fly genetics

The following fly strains were used in this study [obtained from the Bloomington *Drosophila* Stock Center (BDSC)]: *w¹¹¹⁸* or UAS-*lacZ* served as wild-type controls, *dysf²* (BDSC 9590), *dysf³* (BDSC 9591), UAS-*dysf* (BDSC 9592), UAS-*lam::gfp* (BDSC, 7378), UASp-*dsRNA-dysf* (BDSC 35010), *stat92e-stat92e::gfp/Cyo* (BDSC 38670), *gfp-nup107* (BDSC 35514), *msp300-gfp* (BDSC 59757), *stat-lacZ* (BDSC 11681), and UAS-*tai*(Δ B) (BDSC 28273). UAS-*nup153^{RNAi}* (VDR 47155) and *nup153^{NP2104}* (Kyoto 104091) were obtained from Vienna *Drosophila* Resource Center and Kyoto Stock Center (DGRC), respectively. UAS-*dysf-3xHA* was obtained from FlyORF stock (F001839). The Jak/Stat signaling reporter *Stat92E-GFP* was obtained from E. Bach (37). Transgene expression in follicle cells was induced by *slbo-GAL4* (40), *c306-GAL4* (82), or *actin-GAL4/Cyo* (BDSC 4414) at 29°C for 12 to 14 hours. UAS-*upd* (83) and UAS-*hop* (84) were obtained from Yu-Chen Tsai. UAS-*pen* (UASp-*impa2-3xMyc*) was a gift from S. Kobayashi (85). *hsFLP; FRT82B, ubi-rfp* was a gift from Chi Kuang Yao. UAS-*dysf* expression in salivary glands was induced by *24B-GAL4* obtained from Tzu-Yang Lin. To prevent lethality caused by transgene expression during development, we combined *tub-GAL80^{ts}* (BDSC 7019) with a GAL4 system to suppress its effect in embryogenesis. Therefore, flies were raised below or at 25°C until nonpermissive temperature treatment at 31°C for 12 hours to 3 days (86). In the precocious migration experiment, transgenes were induced by *act-GAL4, tub-GAL80^{ts}* and incubated flies at 31°C for 2 days.

The *dysf²* (BDSC 9590) or *dysf^{1W}* alleles were recombined with *FRT82B* (BDSC 2035) to establish the *dysf², FRT82B* and *dysf^{1W}, FRT82B}* lines, which were then crossed to *hsFLP; FRT82B, ubi-gfp/TM3, Sb¹* or *hsFLP; FRT82B, ubi-rfp/TM3, Sb¹* to generate mutant clones. The female flies were heat-shocked at 37°C for 1 hour twice per day for one or three consecutive days and then raised at 25°C for 2 or 5 days on dry yeast and standard fly food before dissection. For the *dysf* knockdown experiment, female flies carrying *actin-GAL4* and UASp-*dsRNA-dysf* were raised at 29°C for 1 to 3 days before dissection. For clonal induction of UAS-*dysf* by Flip-Out technique (87), *hsFLP/UAS-dysf; AyGAL4, UAS-lacZ/Stat92E-GFP* flies were heat-shocked twice at 37°C for 1 hour and then fed with dry yeast and maintained at 29°C for 1 day before dissection.

Generation of an APEX2 knock-in tag at the *dysf* locus

The *dysf^{1W}}* allele was generated by CRISPR-Cas9-mediated genome editing, which was performed by WellGenetics (Taiwan). In brief, the guide RNA (ACGTGGCCTAGACAAGGTGACGG) designed to create a double-strand break at the 5' UTR of the *dysf* locus was cloned into the CRISPR-Cas9 vector pDCC6. APEX2 (a gift from T.-Y. Lin) (88), homology arms, a Piggy Bac terminal repeat, the 3xP3-hsp70 promoter, and DsRed2 were cloned into pUC57-Kan donor plasmid. By microinjection, the transgene, APEX2-PBacDsRed, was inserted into the 5' end of *dysf* coding region by homology-dependent

repair. To kick out the Ds-Red marker and generate *N-APEX2-dysf*, *dysf^{FW}* (fig. S5A) was crossed with *P{Tub-PBac}\T2/wgSp-1* (BL8285) to excise the PBacDsRed fragment (fig. S5A).

Production of anti-phospho-*Drosophila* Stat92E (Tyr⁷⁰⁴) antibody

The phospho-peptide around residue Tyr⁷⁰⁴ of Stat92E was synthesized and conjugated with a KLH peptide, resulting in H-Cys-Glu-Pro-Leu-Val-Leu-Asp-Pro-Val-Thr-Gly-[pTyr]-Val-Lys-Ser [KLH-peptide via Cys82282822 82-OH (89)]. A rabbit was then immunized with the peptide to generate antibodies.

Immunohistochemistry

Before dissection, flies or larvae were fattened on wet or dry yeast for 14 to 16 hours and maintained at 29°C. Egg chambers or salivary glands were dissected and fixed in buffer [4% paraformaldehyde (Electron Microscopy Sciences), 1× phosphate-buffered saline (PBS; Sigma-Aldrich), and 1 mM calcium chloride (Sigma-Aldrich)] on ice for 30 min. For anti-Dysf staining, the fixation time was reduced to 20 min. Samples were then washed three times with 1× PBS buffer containing 0.3% Triton X-100. Washing buffer with 0.5% Triton X-100 was applied for anti-Dysf staining. The following primary antibodies used for immunostaining were obtained from the Developmental Studies Hybridoma Bank (DSHB): mouse anti-FasIII (7G10; 1:10), mouse anti-Eya (*eya10H6*; 1:10), mouse anti-β-galactosidase (40-1a; 1:10), mouse anti-Lamin (ADL67.10; 1:10), and rat anti-DE-cadherin (DCAD2; 1:10). Rabbit anti-Dysf (1:500) was a gift from L. Jiang (Oakland University, USA). Mouse anti-Stat3 (124H6; 1:500) and rabbit anti-p-Stat3 (D3A7; 1:20) were purchased from Cell Signaling Technology. Mouse anti-Lamin A/C (636; 1:100) was ordered from Santa Cruz Biotechnology. Phalloidin (P5282; 1:5000) was purchased from Sigma-Aldrich. For anti-p-Stat staining, flies were dissected in S2 medium containing 10% fetal bovine serum (FBS) and 1× phosphatase inhibitors (PhosSTOP, Sigma-Aldrich) and followed by fixation buffer (4% paraformaldehyde, 1× PBS, and 1× phosphatase inhibitors) at 4°C for 2 hours. Samples were then washed three times with 0.5% PBT (PBS containing 0.5% Triton X-100). The anti-p-Stat antibodies (1:400) were diluted with 0.3% PBT (PBS containing 0.3% Triton X-100) and incubated with samples overnight at 4°C. The following secondary antibodies conjugated with fluorescent dye were used at 1:400 dilutions: Alexa Fluor 488, Alexa Fluor 568, or Alexa Fluor 647 (Invitrogen, Molecular Probes). Nuclei shown in all confocal micrographs were stained with DAPI (Invitrogen; 1:10,000). Fluorescence images were obtained by Zeiss LSM-780 confocal microscopy (Instrument Development Center, NCKU, Taiwan) and processed by ZEN software.

Quantitative assessment of *Stat92E-GFP* expression and anti-p-Stat staining during oogenesis

Micrographs of *Stat92E-GFP* reporter, Stat::GFP signals, and anti-p-Stat staining were obtained by Zeiss LSM 780 confocal microscopy. To ensure that egg chambers at the same stage were used for analysis, we measured their axes along the anterior to posterior direction (90, 91). *Stat92E-GFP*, Stat::GFP expression/anti-p-Stat staining was defined quantitatively by the ratio of fluorescence intensity in anterior follicle cells over that of oocytes at different stages, except for stages 9 to 10 when measurements were taken in border cells. We targeted the nuclear edges of border cells or follicle cells to measure fluorescence intensity with ZEN software. The fluorescence intensity of oocytes

served as an internal control to normalize values of *Stat92E-GFP*, Stat::GFP, and anti-p-Stat.

APEX2 proximity labeling to map protein interactions

The APEX2 labeling protocol was a modification from a previous publication (58). We dissected 120 pairs of fly ovaries in *Drosophila* S2 cell medium and then treated them with 0.3% PBT for 15 min to enhance tissue penetrance, before applying 500 μM Biotin-Phenol (Iris Biotech) for 15 min. After this pretreatment, 1 mM H₂O₂ was added and incubated for 1 min to induce APEX2 to label nearby proteins. The reaction was stopped by means of quencher buffer [5 mM Trolox (Sigma-Aldrich), 10 mM sodium azide (Sigma-Aldrich), and 10 mM sodium ascorbate (Sigma-Aldrich) in PBS]. After biotin labeling, samples were lysed with lysis buffer (50 mM Tris-Cl, 150 mM NaCl, 0.1% SDS, 1% Triton X-100, and 1× protease inhibitor cocktail), before being passed through streptavidin magnetic beads (Thermo Fisher Scientific) to enrich for biotinylated proteins. After purification, samples were subjected to SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and blotted with anti-streptavidin-horseradish peroxidase (HRP; 1:5000; Invitrogen). Fourteen slices of protein interest in gel that include control and experiments were extracted from the PAGE and identified by LC-MS/MS.

Plasmid DNA construction

DNA fragments encoding GST were cloned into the Hind III/Xho I sites of the pET24a vector to generate pET24a-GST, which served as vector for Pen-truncated constructs. Full-length *pen* was amplified by polymerase chain reaction (PCR) using forward (5'-GAATTCATGAGTAAGCGGATTCTAA-3') and reverse (5'-AAGCTTGAACGTGTAGCCACCTC-3') primers from an expressed sequence tag (EST) clone (LD24935) and then subcloned into the Eco RI/Hind III sites of pET24a-GST. Other subdomain deletion constructs were amplified by (i) forward primer (5'-GAATTCATGAGTAAGCGGATTCTAA-3') and reverse primer (5'-AAGCTTGCCATTGAGCTCTTTGAGC-3') for pET24a-Pen (1-63)-GST, (ii) forward primer (5'-GAATTCATGAGTAAGCGGATTCTAA-3') and reverse primer (5'-AAGCTTGATCTTGGTGTATCGTCG-3') for pET24a-Pen (1-275)-GST, (iii) forward primer (5'-GAATTCATGAGTAAGCGGATTCTAA-3') and reverse primer (5'-AAGCTTGTGCCACCAAGTTTCTC-3') for pET24a-Pen (1-447)-GST, and (iv) forward primer (5'-GAATTCATGCCATTTCGATCAGGTGAAG-3') and reverse primer (5'-AAGCTTGAACGTGTAGCCACCTC-3') for pET24a-Pen (234-552)-GST. Full-length *karyopherin* β3 was amplified from EST clone FI07923 by PCR with forward primer (5'-GGTACCGAGCTCATGGTAAGCCTATCCCTAACCCCTCTCCTCGGTCTCGATTCTACGATGGCAGCGGATCAGGCC-3') and reverse primer (5'-GCGGCCGCGGGAGCCAGTTTGC-3'), before being subcloned into the Sac I/Not I site of pDB-6xHis-MBP. Human Npas4 was amplified by PCR with forward primer (5'-AGATCTATGTACCGCTCCACCAAG-3') and reverse primer (5'-CTGCAGAAACGTTGGTTCCCTCC-3') from cDNA of a HeLa cell line and subcloned into the Bgl II/Pst I sites of pEGFP-C1.

Human Kpna2 was amplified by PCR with forward primer (5'-AATGGTTCGCGGATCCATGGATTACAAGGACGACGATGACAAGATGTCCACCAACGAGAATGC-3') and reverse primer (5'-TAGGGGACATAAGCTTAAAGTTAAAGGTCCCAGGAGCC-3') from cDNA of a Hep3B cell line and subcloned into the Eco RI/Hind III sites of pET24a-GST.

Recombinant protein expression

The plasmids encoding GST, Pen (FL)-GST, Pen (1-63)-GST, Pen (1-275)-GST, Pen (1-447)-GST, Pen (234-552)-GST, human Kpna2-GST, MBP, and MBP-Kary β 3 were transformed into *BL21(DE3)*-competent cells (Invitrogen) for protein expression. Fusion protein expression was induced by treatment with 1 mM IPTG (isopropyl- β -D-thiogalactopyranoside) for 24 hours at 18°C. After induction, *Escherichia coli* were resuspended in ice-cold lysis buffer [1× PBS (pH 7.4), 0.3% Triton, 150 mM NaCl, 10% glycerol, 10 mg/ml lysozyme, and 5 mM EDTA] and then sonicated using a ChromTech UP-500 system (10 cycles at 30% amplitude for 5 s on/5 s off). After sonication, lysates were centrifuged at 12,000g at 4°C for 20 min. Supernatants were subjected to affinity purification using Ni²⁺ resin (Invitrogen) or Glutathione Sepharose 4B (GE Healthcare) to collect recombinant proteins. Before pull-down assays, beads binding to recombinant proteins were stored in binding buffer (50 mM tris-Cl, 150 mM NaCl, 0.05% SDS, 1% Triton X-100, and 1× Roche EDTA-free protease inhibitor).

Tissue extract preparation

Dysf-3xHA (UAS-*dysf-3xHA*, *tubGAL80^{ts}*) was overexpressed by *slbo-GAL4* in follicle cells. Female flies were kept at 25°C for 4 days and then shifted to 31°C for 1 day before dissection. We dissected 400 pairs of ovaries from female flies overexpressing UAS-*dysf-3xHA* in *Drosophila* S2 cell medium (Thermo Fisher Scientific) and then lysed them in 200 μ l of radioimmunoprecipitation assay buffer (50 mM tris-Cl, 150 mM NaCl, 0.1% SDS, 1% Triton X-100, and 1× EDTA-free protease inhibitor). The ovary lysate was kept on ice and sonicated (ChromTech UP-500) for 10 cycles at 30% amplitude for 5 s on/10 s off. After sonication, lysates were centrifuged at 15,000g at 4°C for 20 min. The supernatant was applied for pull-down assay. Tissue was harvested from *24B-GAL4>UAS-dysf-3xHA, tubGAL80^{ts}* larvae maintained at 25°C for 4 days and then shifted to 31°C for 1 day before dissection and extraction of Dysf-3xHA. Tissue was harvested from *stat92e-stat92e::gfp* larvae kept at 25°C for 5 days before dissection and extraction of Stat::Flag. Salivary glands and imaginal discs from 200 larvae were dissected in S2 cell medium and lysed as described above for ovary extract preparation. All lysates were incubated with deoxyribonuclease I (6 U/ml; NEB) at 4°C for 30 min before undergoing pull-down assay.

Cell extract preparation

The Hep3B cells were incubated in coimmunoprecipitation (co-IP) buffer [50 mM tris-HCl, 120 mM NaCl (pH 8.0), 0.05 mM EDTA, 0.5% Triton-100, and 1× protease inhibitor] and rocked at 200 rpm for 15 min on ice. Then, cells were transferred to Eppendorf tubes and centrifuged at 12,000 rpm for 5 min at 4°C. The supernatant was collected before pull-down assay and co-IP.

Pull-down assay

Beads bound to recombinant proteins were incubated with tissue lysates at 4°C for 3 hours to overnight and then washed three times with wash buffer I (50 mM tris-Cl, 150 mM NaCl, 1% Triton X-100, and 1× Roche EDTA-free protease inhibitor). Last, high-salt wash buffer II (50 mM tris-Cl, 500 mM NaCl, 1% Triton X-100, and 1× EDTA-free protease inhibitor) was used to wash beads three times to avoid nonspecific binding, before being subjected to SDS-PAGE and Western blot detection. Anti-HA (1:3000; Ab9110, Abcam), anti-Flag (1:1000; M2, Sigma-Aldrich), and anti-MBP (1:1000; 2A1,

DSHB) were used to detect transgenic proteins fused with indicated tags.

Co-IP assay

The GFP primary antibody was added into the cell extract and incubated with rotation at 4°C for 2 to 3 hours. About 35 to 40 μ l of protein A/G beads that were prewashed with co-IP buffer were then added and incubated with rotation at 4°C for 1 hour. Captured immunoprecipitates were washed three times with lysis washing buffer and two times with 1× PBS. Immunoprecipitated proteins were denatured and subjected to immunoblot analysis using the following antibodies: anti-GFP (1:5000; JL-8, Clontech) and anti-Kpna2 (1:10,000; ab70160, Abcam).

Analysis of Dysf subcellular localization by PLAs

Our PLA protocol was modified from the Duolink In Situ Red Starter Kit Mouse/Rabbit (Sigma-Aldrich) protocol. The following primary antibodies were used: rabbit anti-Dysf (1:1000; in-house), mouse anti-Lamin (1:100; ADL67.10, DSHB), mouse anti-GFP (1:1000; 6AT316, Abcam), mouse anti-mab414 (1:1000; ab24609, Abcam), and KLAR-C (1:10; 9C10, DSHB).

Ovarioles were dissected in S2 cell medium after fattening for 2 days on dry yeast. Tissues were then fixed on ice with 4% paraformaldehyde in PBS buffer for 30 min. After fixation, the egg chambers were rinsed with 0.5% PBT for 10 min before being transferred to a 4°C refrigerator with gentle shaking overnight. The samples were then incubated overnight with primary antibody in 0.5% PBT at 4°C. The egg chambers were washed three times for 40 min with 0.5% PBT before being incubated in PLA probe solution (plus and minus probe diluted 1:5 in 0.5% PBT) at room temperature. After a 1-hour reaction in PLA solution, the samples were washed twice with wash buffer A from kit for 5 min, followed by 30-min ligation at 37°C. Samples were further washed twice with buffer A for 5 min and then incubated in amplification solution for 100 min at 37°C. After sequential rinsing with buffer B and then 0.01× buffer B from kit for 5 min each, samples were transferred to mounting medium containing DAPI and stored at 4°C. Stage 2 to 3 egg chambers were imaged by means of Zeiss LSM 780 confocal microscopy, and PLA signals were assessed quantitatively using Fiji ImageJ software. Pixel values less than or greater than that of the negative control (lacking anti-Dysf) were deemed as displaying no interaction or positive interaction, respectively.

Cell culture, transfection, and IL-6 treatment

Hep3B and HCT116 cells were purchased from BCRC (Food Industry Research and Development Institute, Taiwan). Hep3B cells were maintained in Dulbecco's modified Eagle's medium (high glucose, 1954626, Gibco). HCT116 cells were maintained in RPMI 1640 medium (31800022, Gibco). GFP and GFP::Npas4 were transfected into Hep3B and HCT116 by PolyJet and Lipofectamine 2000, respectively, according to the manufacturers' instructions. For IL-6 treatment, cells were starved for 18 hours by maintaining them on serum-free medium before being subjected to IL-6 (25 ng/ml; GF338, Millipore) treatment at the indicated time points.

Migration assay

We seeded 8×10^4 cells suspended in FBS-free medium in the upper chamber of a 24-well transwell system (pore size 8 μ m, BD Biosciences). Culture medium containing 10% FBS or conditioned medium was

added to the lower chamber. After 48-hour incubation, migrated cells were fixed with methanol for 20 min and then stained with 0.1% crystal violet. Numbers of migrated cells were counted under optical microscopy in five random fields, and an average number is presented as mean \pm SEM.

SUPPLEMENTARY MATERIALS

Supplementary material for this article is available at <https://science.org/doi/10.1126/sciadv.abm2411>

[View/request a protocol for this paper from Bio-protocol.](#)

REFERENCES AND NOTES

- C. H. Stuelten, C. A. Parent, D. J. Montell, Cell motility in cancer invasion and metastasis: Insights from simple model organisms. *Nat. Rev. Cancer* **18**, 296–312 (2018).
- D. R. Welch, D. R. Hurst, Defining the hallmarks of metastasis. *Cancer Res.* **79**, 3011–3027 (2019).
- V. Guglielmi, S. Sakuma, M. A. D'Angelo, Nuclear pore complexes in development and tissue homeostasis. *Development* **147**, (2020).
- C. Hogarth, C. Itman, D. A. Jans, K. L. Loveland, Regulated nucleocytoplasmic transport in spermatogenesis: A driver of cellular differentiation? *Bioessays* **27**, 1011–1025 (2005).
- M. Raices, L. Bukata, S. Sakuma, J. Borlido, L. S. Hernandez, D. O. Hart, M. A. D'Angelo, Nuclear pores regulate muscle development and maintenance by assembling a localized Mef2C complex. *Dev. Cell* **41**, 540–554.e7 (2017).
- C. Fallini, B. Khalil, C. L. Smith, W. Rossoll, Traffic jam at the nuclear pore: All roads lead to nucleocytoplasmic transport defects in ALS/FTD. *Neurobiol. Dis.* **140**, 104835 (2020).
- A. Satomura, J. H. Brickner, Nuclear pore complexes: A scaffold regulating developmental transcription? *Trends Cell Biol.* **27**, 621–622 (2017).
- D. E. Levy, J. E. Darnell Jr., Stats: Transcriptional control and biological impact. *Nat. Rev. Mol. Cell Biol.* **3**, 651–662 (2002).
- X. Hu, J. Li, M. Fu, X. Zhao, W. Wang, The JAK/STAT signaling pathway: From bench to clinic. *Signal Transduct. Target. Ther.* **6**, 402 (2021).
- S. C. Herrera, E. A. Bach, JAK/STAT signaling in stem cells and regeneration: From *Drosophila* to vertebrates. *Development* **146**, (2019).
- S. Ernst, G. Muller-Newen, Nucleocytoplasmic shuttling of STATs. A target for intervention? *Cancers (Basel)* **11**, 1815 (2019).
- R. Ushijima, N. Sakaguchi, A. Kano, A. Maruyama, Y. Miyamoto, T. Sekimoto, Y. Yoneda, K. Ogino, T. Tachibana, Extracellular signal-dependent nuclear import of STAT3 is mediated by various importin alphas. *Biochem. Biophys. Res. Commun.* **330**, 880–886 (2005).
- K. L. Owen, N. K. Brockwell, B. S. Parker, JAK-STAT signaling: A double-edged sword of immune regulation and cancer progression. *Cancers* **11**, 2002 (2019).
- M. P. Zeidler, N. Bausek, The *Drosophila* JAK-STAT pathway. *JAKSTAT* **2**, e25353 (2013).
- H. Yu, D. Pardoll, R. Jove, STATs in cancer inflammation and immunity: A leading role for STAT3. *Nat. Rev. Cancer* **9**, 798–809 (2009).
- S. Trivedi, M. Starz-Gaiano, *Drosophila* Jak/STAT signaling: Regulation and relevance in human cancer and metastasis. *Int. J. Mol. Sci.* **19**, 4056 (2018).
- A. Betz, N. Lampen, S. Martinek, M. W. Young, J. E. Darnell Jr., A *Drosophila* PIAS homologue negatively regulates stat92E. *Proc. Natl. Acad. Sci. U.S.A.* **98**, 9563–9568 (2001).
- R. Starr, D. J. Hilton, Negative regulation of the JAK/STAT pathway. *Bioessays* **21**, 47–52 (1999).
- W. S. Alexander, D. J. Hilton, The role of suppressors of cytokine signaling (SOCS) proteins in regulation of the immune response. *Annu. Rev. Immunol.* **22**, 503–529 (2004).
- J. S. Rawlings, G. Rennebeck, S. M. Harrison, R. Xi, D. A. Harrison, Two *Drosophila* suppressors of cytokine signaling (SOCS) differentially regulate JAK and EGFR pathway activities. *BMC Cell Biol.* **5**, 38 (2004).
- P. Karsten, S. Hader, M. P. Zeidler, Cloning and expression of *Drosophila* SOCS36E and its potential regulation by the JAK/STAT pathway. *Mech. Dev.* **117**, 343–346 (2002).
- B. A. Callus, B. Mathey-Prevot, SOCS36E, a novel *Drosophila* SOCS protein, suppresses JAK/STAT and EGF-R signalling in the imaginal wing disc. *Oncogene* **21**, 4812–4821 (2002).
- A. J. Monahan, M. Starz-Gaiano, Socs36E attenuates STAT signaling to optimize motile cell specification in the *Drosophila* ovary. *Dev. Biol.* **379**, 152–166 (2013).
- D. L. Silver, D. J. Montell, Paracrine signaling through the JAK/STAT pathway activates invasive behavior of ovarian epithelial cells in *Drosophila*. *Cell* **107**, 831–841 (2001).
- D. L. Silver, E. R. Geisbrecht, D. J. Montell, Requirement for JAK/STAT signaling throughout border cell migration in *Drosophila*. *Development* **132**, 3483–3492 (2005).
- H. Jiang, P. H. Patel, A. Kohlmaier, M. O. Grenley, D. G. McEwen, B. A. Edgar, Cytokine/Jak/Stat signaling mediates regeneration and homeostasis in the *Drosophila* midgut. *Cell* **137**, 1343–1355 (2009).
- Y. Verhoeven, S. Tilborghs, J. Jacobs, J. de Waele, D. Quatannens, C. Deben, H. Prene, P. Pauwels, X. B. Trinh, A. Wouters, E. L. J. Smits, F. Lardon, P. A. van Dam, The potential and controversy of targeting STAT family members in cancer. *Semin. Cancer Biol.* **60**, 41–56 (2020).
- R. Xi, J. R. McGregor, D. A. Harrison, A gradient of JAK pathway activity patterns the anterior-posterior axis of the follicular epithelium. *Dev. Cell* **4**, 167–177 (2003).
- I. L. Torres, H. Lopez-Schier, D. S. Johnston, A Notch/Delta-dependent relay mechanism establishes anterior-posterior polarity in *Drosophila*. *Dev. Cell* **5**, 547–558 (2003).
- E. Assa-Kunik, I. L. Torres, E. D. Schejter, D. S. Johnston, B. Z. Shilo, *Drosophila* follicle cells are patterned by multiple levels of Notch signaling and antagonism between the Notch and JAK/STAT pathways. *Development* **134**, 1161–1169 (2007).
- X. Wang, J. Bo, T. Bridges, K. D. Dugan, T. C. Pan, L. A. Chodosh, D. J. Montell, Analysis of cell migration using whole-genome expression profiling of migratory cells in the *Drosophila* ovary. *Dev. Cell* **10**, 483–495 (2006).
- L. Borghese, G. Fletcher, J. Mathieu, A. Atzberger, W. C. Eades, R. L. Cagan, P. Rørth, Systematic analysis of the transcriptional switch inducing migration of border cells. *Dev. Cell* **10**, 497–508 (2006).
- M. Starz-Gaiano, M. Melani, X. Wang, H. Meinhardt, D. J. Montell, Feedback inhibition of Jak/STAT signaling by apotic is required to limit an invasive cell population. *Dev. Cell* **14**, 726–738 (2008).
- W. H. Yoon, H. Meinhardt, D. J. Montell, miRNA-mediated feedback inhibition of JAK/STAT morphogen signalling establishes a cell fate threshold. *Nat. Cell Biol.* **13**, 1062–1069 (2011).
- Y. Hu, I. Flockhart, A. Vinayagam, C. Bergwitz, B. Berger, N. Perrimon, S. E. Mohr, An integrative approach to ortholog prediction for disease-focused and other functional studies. *BMC Bioinformatics* **12**, 357 (2011).
- A. C. Jang, Y. C. Chang, J. Bai, D. Montell, Border-cell migration requires integration of spatial and temporal signals by the BTB protein Abrupt. *Nat. Cell Biol.* **11**, 569–579 (2009).
- E. A. Bach, L. A. Ekas, A. Ayala-Camargo, M. S. Flaherty, H. Lee, N. Perrimon, G. H. Baeg, GFP reporters detect the activation of the *Drosophila* JAK/STAT pathway in vivo. *Gene Expr. Patterns* **7**, 323–331 (2007).
- N. Deneff, T. Schupbach, Patterning: JAK-STAT signalling in the *Drosophila* follicular epithelium. *Curr. Biol.* **13**, R388–R390 (2003).
- A. H. Brand, N. Perrimon, Targeted gene expression as a means of altering cell fates and generating dominant phenotypes. *Development* **118**, 401–415 (1993).
- P. Rørth, K. Szabo, A. Bailey, T. Laverty, J. Rehm, G. M. Rubin, K. Weigmann, M. Milan, V. Benes, W. Ansorge, S. M. Cohen, Systematic gain-of-function genetics in *Drosophila*. *Development* **125**, 1049–1057 (1998).
- J. Bai, D. Montell, Eyes absent, a key repressor of polar cell fate during *Drosophila* oogenesis. *Development* **129**, 5377–5388 (2002).
- K. Ito, H. Sass, J. Urban, A. Hofbauer, S. Schneuwly, GAL4-responsive UAS-tau as a tool for studying the anatomy and development of the *Drosophila* central nervous system. *Cell Tissue Res.* **290**, 1–10 (1997).
- Y. C. Chang, J. W. Wu, Y. C. Hsieh, T. H. Huang, Z. M. Liao, Y. S. Huang, J. A. Mondo, D. Montell, A. C. C. Jang, Rap1 negatively regulates the hippo pathway to polarize directional protrusions in collective cell migration. *Cell Rep.* **22**, 2160–2175 (2018).
- R. Yan, S. Small, C. Desplan, C. R. Dearolf, J. E. Darnell Jr., Identification of a Stat gene that functions in *Drosophila* development. *Cell* **84**, 421–430 (1996).
- C. Schindler, J. E. Darnell Jr., Transcriptional responses to polypeptide ligands: The JAK-STAT pathway. *Annu. Rev. Biochem.* **64**, 621–652 (1995).
- L. Jiang, S. T. Crews, Dysfusion transcriptional control of *Drosophila* tracheal migration, adhesion, and fusion. *Mol. Cell Biol.* **26**, 6547–6556 (2006).
- L. Jiang, S. T. Crews, Transcriptional specificity of *Drosophila* dysfusion and the control of tracheal fusion cell gene expression. *J. Biol. Chem.* **282**, 28659–28668 (2007).
- S. Cordoba, C. Estella, The bHLH-PAS transcription factor dysfusion regulates tarsal joint formation in response to Notch activity during *drosophila* leg development. *PLOS Genet.* **10**, e1004621 (2014).
- M. P. Zeidler, N. Perrimon, D. I. Strutt, Polarity determination in the *Drosophila* eye: A novel role for unpaired and JAK/STAT signaling. *Genes Dev.* **13**, 1342–1353 (1999).
- L. Jiang, S. T. Crews, The *Drosophila* dysfusion basic helix-loop-helix (bHLH)-PAS gene controls tracheal fusion and levels of the tracheal bHLH-PAS protein. *Mol. Cell Biol.* **23**, 5625–5637 (2003).
- O. Söderberg, M. Gullberg, M. Jarvius, K. Ridderstråle, K.-J. Leuchowius, J. Jarvius, K. Wester, P. Hydbring, F. Bahram, L.-G. Larsson, U. Landegren, Direct observation of individual endogenous protein complexes in situ by proximity ligation. *Nat. Methods* **3**, 995–1000 (2006).
- K. M. Mannix, R. M. Starble, R. S. Kaufman, L. Cooley, Proximity labeling reveals novel interactomes in live *Drosophila* tissue. *Development* **146**, dev176644 (2019).
- R. Becker, M. Leone, F. B. Engel, Microtubule organization in striated muscle cells. *Cell* **9**, 1395 (2020).

54. M. Palka, A. Tomczak, K. Grabowska, M. Machowska, K. Piekawicz, D. Rzepecka, R. Rzepecki, Laminopathies: What can humans learn from fruit flies. *Cell. Mol. Biol. Lett.* **23**, 32 (2018).
55. S. Sotillos, M. Krahn, J. M. Espinosa-Vazquez, J. C. Hombria, Src kinases mediate the interaction of the apical determinant Bazooka/PAR3 with STAT92E and increase signalling efficiency in *Drosophila* ectodermal cells. *Development* **140**, 1507–1516 (2013).
56. Y. Hayashi, T. R. Sexton, K. Dejima, D. W. Perry, M. Takemura, S. Kobayashi, H. Nakato, D. A. Harrison, Glypicans regulate JAK/STAT signaling and distribution of the Unpaired morphogen. *Development* **139**, 4162–4171 (2012).
57. C. L. Chen, Y. Hu, N. D. Udeshi, T. Y. Lau, F. Wirtz-Peitz, L. He, A. Y. Ting, S. A. Carr, N. Perrimon, Proteomic mapping in live *Drosophila* tissues using an engineered ascorbate peroxidase. *Proc. Natl. Acad. Sci. U.S.A.* **112**, 12093–12098 (2015).
58. V. Hung, N. D. Udeshi, S. S. Lam, K. H. Loh, K. J. Cox, K. Pedram, S. A. Carr, A. Y. Ting, Spatially resolved proteomic mapping in living cells with the engineered peroxidase APEX2. *Nat. Protoc.* **11**, 456–475 (2016).
59. B. Kobe, Autoinhibition by an internal nuclear localization signal revealed by the crystal structure of mammalian importin α . *Nat. Struct. Biol.* **6**, 388–397 (1999).
60. D. Gorlich, P. Henklein, R. A. Laskey, E. Hartmann, A 41 amino acid motif in importin- α confers binding to importin- β and hence transit into the nucleus. *EMBO J.* **15**, 1810–1817 (1996).
61. S. J. Lee, Y. Matsuura, S. M. Liu, M. Stewart, Structural basis for nuclear import complex dissociation by RanGTP. *Nature* **435**, 693–696 (2005).
62. A. Dickmanns, R. H. Kehlenbach, B. Fahrenkrog, Nuclear pore complexes and nucleocytoplasmic transport: From structure to function to disease. *Int. Rev. Cell Mol. Biol.* **320**, 171–233 (2015).
63. L. K. Davis, A. Saric, B. W. Hoogenboom, A. Zilman, Physical modeling of multivalent interactions in the nuclear pore complex. *Biophys. J.* **120**, 1565–1577 (2021).
64. H. Yu, H. Lee, A. Herrmann, R. Buettner, R. Jove, Revisiting STAT3 signalling in cancer: New and unexpected biological functions. *Nat. Rev. Cancer* **14**, 736–746 (2014).
65. J. F. Bromberg, M. H. Wrzeszczynska, G. Devgan, Y. Zhao, R. G. Pestell, C. Albanese, J. E. Darnell Jr., Stat3 as an oncogene. *Cell* **98**, 295–303 (1999).
66. C. Pilati, J. Zucman-Rossi, Mutations leading to constitutive active gp130/JAK1/STAT3 pathway. *Cytokine Growth Factor Rev.* **26**, 499–506 (2015).
67. J. G. Turner, E. Dawson, C. L. Cubitt, R. Baz, D. M. Sullivan, Inhibition of CRM1-dependent nuclear export sensitizes malignant cells to cytotoxic and targeted agents. *Semin. Cancer Biol.* **27**, 62–73 (2014).
68. Y.-C. Chang, J.-W. Wu, C.-W. Wang, A. C.-C. Jang, Hippo Signaling-mediated Mechanotransduction in cell movement and cancer metastasis. *Front. Mol. Biosci.* **6**, 157 (2020).
69. A. C. Jang, M. Starz-Gaiano, D. J. Montell, Modeling migration and metastasis in *Drosophila*. *J. Mammary Gland Biol. Neoplasia* **12**, 103–114 (2007).
70. M. Ghandi, F. W. Huang, J. Jané-Valbuena, G. V. Kryukov, C. C. Lo, E. R. McDonald III, J. Barretina, E. T. Gelfand, C. M. Bielski, H. Li, K. Hu, A. Y. Andreev-Drakhlin, J. Kim, J. M. Hess, B. J. Haas, F. Aguet, B. A. Weir, M. V. Rothberg, B. R. Paoletta, M. S. Lawrence, R. Akbani, Y. Lu, H. L. Tiv, P. C. Gokhale, A. A. Mansour, C. Oh, J. Shih, K. Hadi, Y. Rosen, J. Bistline, K. Venkatesan, A. Reddy, D. Sonkin, M. Liu, J. Lehar, J. M. Korn, D. A. Porter, M. D. Jones, J. Golji, G. Caponigro, J. E. Taylor, C. M. Dunning, A. L. Creech, A. C. Warren, J. M. McFarland, M. Zamanighomi, A. Kauffmann, N. Stransky, M. Imielinski, Y. E. Maruvka, A. D. Cherniack, A. Tsherniak, F. Vazquez, J. D. Jaffe, A. A. Lane, D. M. Weinstock, C. M. Johannessen, M. P. Morrissey, F. Stegmeier, R. Schlegel, W. C. Hahn, G. Getz, G. B. Mills, J. S. Boehm, T. R. Golub, L. A. Garraway, W. R. Sellers, Next-generation characterization of the Cancer Cell Line Encyclopedia. *Nature* **569**, 503–508 (2019).
71. D. P. Nusinow, J. Szpyt, M. Ghandi, C. M. Rose, E. R. McDonald III, M. Kalocsay, J. Jané-Valbuena, E. Gelfand, D. K. Schweppe, M. Jedrychowski, J. Golji, D. A. Porter, T. Rejtar, Y. K. Wang, G. V. Kryukov, F. Stegmeier, B. K. Erickson, L. A. Garraway, W. R. Sellers, S. P. Gygi, Quantitative proteomics of the cancer cell line encyclopedia. *Cell* **180**, 387–402.e16 (2020).
72. X. Sun, Y. Lin, Npas4: Linking neuronal activity to memory. *Trends Neurosci.* **39**, 264–275 (2016).
73. Y. Teng, J. L. Ross, J. K. Cowell, The involvement of JAK-STAT3 in cell motility, invasion, and metastasis. *JAKSTAT* **3**, e28086 (2014).
74. S. Frey, R. P. Richter, D. Gorlich, FG-rich repeats of nuclear pore proteins form a three-dimensional meshwork with hydrogel-like properties. *Science* **314**, 815–817 (2006).
75. L. E. Kaposos, B. Huang, C. Rencurel, R. Y. H. Lim, Karyopherins regulate nuclear pore complex barrier and transport function. *J. Cell Biol.* **216**, 3609–3624 (2017).
76. A. R. Lowe, J. H. Tang, J. Yassif, M. Graf, W. Y. C. Huang, J. T. Groves, K. Weis, J. T. Liphardt, Importin- β modulates the permeability of the nuclear pore complex in a Ran-dependent manner. *eLife* **4**, e04052 (2015).
77. M. T. Harreman, M. R. Hodel, P. Fanara, A. E. Hodel, A. H. Corbett, The auto-inhibitory function of importin alpha is essential in vivo. *J. Biol. Chem.* **278**, 5854–5863 (2003).
78. E. Butturini, A. Carcereri de Prati, S. Mariotto, Redox regulation of STAT1 and STAT3 signaling. *Int. J. Mol. Sci.* **21**, 7034 (2020).
79. D. A. Frank, STAT3 as a central mediator of neoplastic cellular transformation. *Cancer Lett.* **251**, 199–210 (2007).
80. D. E. Johnson, R. A. O'Keefe, J. R. Grandis, Targeting the IL-6/JAK/STAT3 signalling axis in cancer. *Nat. Rev. Clin. Oncol.* **15**, 234–248 (2018).
81. Z. Qureshy, D. E. Johnson, J. R. Grandis, Targeting the JAK/STAT pathway in solid tumors. *J. Cancer Metastasis Treat.* **6**, 27 (2020).
82. L. Manseau, A. Baradaran, D. Brower, A. Budhu, F. Elefant, H. Phan, A. V. Philp, M. Yang, D. Glover, K. Kaiser, K. Palter, S. Selleck, GAL4 enhancer traps expressed in the embryo, larval brain, imaginal discs, and ovary of *Drosophila*. *Dev. Dyn.* **209**, 310–322 (1997).
83. Y. C. Tsai, Y. H. Sun, Long-range effect of upd, a ligand for Jak/STAT pathway, on cell cycle in *Drosophila* eye development. *Genesis* **39**, 141–153 (2004).
84. D. A. Harrison, R. Binari, T. S. Nahreini, M. Gilman, N. Perrimon, Activation of a *Drosophila* Janus kinase (JAK) causes hematopoietic neoplasia and developmental defects. *EMBO J.* **14**, 2857–2865 (1995).
85. M. Asaoka, K. Hanyu-Nakamura, A. Nakamura, S. Kobayashi, Maternal Nanos inhibits Importin- α 2/Pendulin-dependent nuclear import to prevent somatic gene expression in the *Drosophila* germline. *PLoS Genet.* **15**, e1008090 (2019).
86. S. E. McGuire, Z. Mao, R. L. Davis, Spatiotemporal gene expression targeting with the TARGET and gene-switch systems in *Drosophila*. *Sci. STKE* **2004**, pl6 (2004).
87. K. Ito, W. Awano, K. Suzuki, Y. Hiromi, D. Yamamoto, The *Drosophila* mushroom body is a quadruple structure of clonal units each of which contains a virtually identical set of neurones and glial cells. *Development* **124**, 761–771 (1997).
88. S. S. Lam, J. D. Martell, K. J. Kamer, T. J. Deerinck, M. H. Ellisman, V. K. Mootha, A. Y. Ting, Directed evolution of APEX2 for electron microscopy and proximity labeling. *Nat. Methods* **12**, 51–54 (2015).
89. J. Li, W. Li, H. C. Calhoun, F. Xia, F. B. Gao, W. X. Li, Patterns and functions of STAT activation during *Drosophila* embryogenesis. *Mech. Dev.* **120**, 1455–1468 (2003).
90. A. C. Spradling, Developmental Genetics of Oogenesis, in *The Development of Drosophila melanogaster* (CSH Laboratory Press, 1993), pp. 1–70.
91. D. Y. Chen, J. Crest, S. J. Streichan, D. Bilder, Extracellular matrix stiffness cues junctional remodeling for 3D tissue elongation. *Nat. Commun.* **10**, 3339 (2019).

Acknowledgments: We thank Y. Henry Sun, Lan Jiang, T.-Y. Lin, C.-K. Yao, Min-Lang Huang, S. Kobayashi, and the Taiwan Fly Core for providing fly stocks. We thank the Bloomington *Drosophila* Stock Center, FlyORF, Vienna *Drosophila* Resource Center, and Kyoto Stock Center. We also thank Tzong-Yueh Chen and the technical support team of the Instrument Development Center of NCKU for providing critical assistance with Carl Zeiss LSM 780 laser-scanning micrograph imaging. **Funding:** This research was supported by MOST (Ministry of Science and Technology, R.O.C.) grants to A.C.-C.J., MOST 110-2311-B-006-005 and MOST 107-2311-B-006-002-MY3, and to Y.-C.C., MOST 110-2311-B-110-004-MY3. **Author contributions:** J.-W.W. conducted most experiments. C.-W.W. performed PLA and fluorescence intensity analyses. R.-Y.C. and L.-Y.H. contributed to Fig. 7. Y.-C.T. generated p-Stat antibody. Y.-T.C. carried out the modifier screen. A.C.-C.J. and Y.-C.C. designed and performed experiments, interpreted the data, and wrote the manuscript. **Competing interests:** The authors declare that they have no competing interests. **Data and materials availability:** All data needed to evaluate the conclusions in the paper are present in the paper and/or the Supplementary Materials.

Submitted 3 September 2021

Accepted 7 June 2022

Published 22 July 2022

10.1126/sciadv.abm2411